Movement Alert｜EVEREST MED falls 7.36% in Regular Trading, UBS downgrade to Neutral weighs on sentiment

Market Focus10-23

On October 23, EVEREST MED fell 7.36% intraday in Regular Trading, trading at HK$30.48, with turnover of HK$45.84 million.

The clearest catalyst is an investment-bank view change: UBS downgraded the stock to Neutral and set a target price of RMB27, pressuring near-term risk appetite and prompting profit-taking.

Background context indicates the stock had rallied in recent sessions on optimism around its mRNA platform global clinical development, including the appointment of two former Moderna core scientists and clinical progress for EVM16 and EVM14. After that expectation-driven run-up, the downgrade appears to have become the latest direct trigger for the pullback.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment